Search Results

You are looking at 101 - 110 of 1,090 items for :

  • "community" x
  • Refine by Access: All x
Clear All
Full access

Optimizing Systemic Therapy for Bladder Cancer

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

within the urologic community that the 9% increase in disease-specific survival is of small magnitude. 24 Adjuvant Chemotherapy The NCCN Guidelines confer a category 2B recommendation (lower-level of evidence and consensus) for use of adjuvant

Full access

QIM119-120: Utilizing Technology to Identify Oncology Patients to Impact Patient Care

Brook Blackmore, Nicole Centers, and Troy Gifford

in a community health system is feasible and associated with multiple benefits. Increased navigator patient volumes and navigator productivity were observed. Navigator time spent with patients and physicians increased with a concurrent reduction in

Full access

CLO19-055: Implementing Scalp Cooling: Considerations and Best Practice

Brittany Unthank, Lynne Laurence Brophy, Lindsey Radcliff, Heidi Basinger, and Sabrenna Bourque

satisfaction data will be disseminated. Conclusion: The oncology community is eager to provide patients with scalp cooling, but no literature to date has described the management aspects of implementation. This presentation will offer comprehensive

Full access

Practice Patterns, Guideline-Based Treatments, Costs and Efficacy of Care, and Global Perspectives: A Call for Papers on Excellence in Cancer Care

Harold J. Burstein

in cancer care, from both academic and community perspectives. We are particularly seeking original research and insightful commentary on the best ways to use resources and improve outcomes for patients. Examples of such contributions might include

Full access

Creating An Adolescent and Young Adult Cancer Program: Lessons Learned From Pediatric and Adult Oncology Practice Bases

Damon Reed, Rebecca G. Block, and Rebecca Johnson

, creating dedicated patient care facilities, and educating the community about AYA oncology. Program development during the first 2 years addressed the most glaring unmet needs of AYAs treated in a pediatric hospital. Institutional approval was obtained to

Full access

Preliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncology

Edward C. Li and Jessica DeMartino

community focus on cancer care, it is critical that the oncology community be actively involved in the development and implementation of processes at all levels. To address the knowledge gap problem with CER, consideration must be given to the current

Full access

Rapid Access to Mental Health Professionals With Experience in Treating Cancer-Related Distress: The American Psychosocial Oncology Referral Helpline

Elizabeth Harvey, Lauren Rogak, Ruth Ford, and Jimmie Holland

of psychologists, social workers, nurses, counselors, and psychiatrists, it has maintained a helpline (1-866-276-7443) since 2003 to help patients find a counselor in their local community through a directory maintained by the society. This can serve

Full access

Ovarian Cancer Guidelines: Treatment Progress and Controversies

Robert J. Morgan Jr.

therapeutic developments. Nonetheless, significant controversies remain, and these controversies can cause major disagreement among experts. This issue of JNCCN proves this point and also illustrates the importance that we in the medical community must place

Full access

Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg

disease response or tumor type: results from a prospective community oncology study. Procrit Study Group . J Clin Oncol 1998 ; 16 : 3412 – 3425 . 10 Gabrilove JL Cleeland CS Livingston RB . Clinical evaluation of once-weekly dosing of

Full access

Accelerating Advances in Cancer Care Research: A Lookback at the 21st Century Cures Act in 2020

Leigh Gallo, Ronald S. Walters, Jeff Allen, Jenny Ahlstrom, Clay Alspach, Yelak Biru, Alyssa Schatz, Kara Martin, and Robert W. Carlson

–agnostic approvals that were based on common genetic alterations rather than the tissue of origin. The OCE coordinated work across the various medical product centers throughout the FDA, and with the cancer research community, to make these advancements possible